Pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene

被引:11
作者
Kondoh, K [1 ]
Nakata, Y [1 ]
Furuta, T [1 ]
Hosoda, F [1 ]
Gamou, T [1 ]
Kurosawa, Y [1 ]
Kinoshita, A [1 ]
Ohki, M [1 ]
Tomita, Y [1 ]
Mori, T [1 ]
机构
[1] Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, Tokyo 1608582, Japan
关键词
secondary leukemia; AML1-MTG16; acute promyelocytic leukemia; t(16; 21)(q24; q22);
D O I
10.1080/10428190290006242
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A chimeric gene, AML1-MTG16, showing high homology to AML1-MTG8, was recently identified in adult leukemic patients with the abnormal karyotype t(16;21)(q24;q22). We recently saw a child patient of 11 years of age who developed acute myelogenous leukemia with the karyotype t(I 6;2 l)(q24;q22), 11 months after autologous peripheral blood stem-cell transplantation (PBSCT) for acute promyelocytic leukemia with karyotype t(15;17)(q22;q11). The reciprocal translocation was localized by fluorescence in situ hybridization (FISH) analysis, reverse transcription polymerase chain reaction (RT-PCR), and Southern blot analysis of bone marrow blood cells and peripheral blood cells. FISH analysis identified a reciprocal translocation between chromosomes 16 and 21. RT-PCR analysis identified expression of the chimeric gene AML1-MTG16. Southern blot analysis revealed a breakpoint occurring at a 1.4 kb Eco RI fragment between exons 3 and 4 of MTG16. The break-point is within the same region as that of secondary leukemias, which has been reported previously. This case suggests the possibility that the region of the breakpoint of MTG16 is a characteristic of secondary leukemia.
引用
收藏
页码:415 / 420
页数:6
相关论文
共 15 条
[1]   Secondary acute myeloblastic leukemia with t(16;21)(q24;q22) involving the AML1 gene [J].
Berger, R ;
LeConiat, M ;
Romana, SP ;
Jonveaux, P .
HEMATOLOGY AND CELL THERAPY, 1996, 38 (02) :183-186
[2]   Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites [J].
Broeker, PLS ;
Super, HG ;
Thirman, MJ ;
Pomykala, H ;
Yonebayashi, Y ;
Tanabe, S ;
ZeleznikLe, N ;
Rowley, JD .
BLOOD, 1996, 87 (05) :1912-1922
[3]  
Cimino G, 1997, CANCER RES, V57, P2879
[4]   Secondary leukemias induced by topoisomerase-targeted drugs [J].
Felix, CA .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :233-255
[5]   The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family [J].
Gamou, T ;
Kitamura, E ;
Hosoda, F ;
Shimizu, K ;
Shinohara, K ;
Hayashi, Y ;
Nagase, T ;
Yokoyama, Y ;
Ohki, M .
BLOOD, 1998, 91 (11) :4028-4037
[6]   Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO [J].
Gelmetti, V ;
Zhang, JS ;
Fanelli, M ;
Minucci, S ;
Pelicci, PG ;
Lazar, MA .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :7185-7191
[7]  
GU Y, 1994, CANCER RES, V54, P2326
[8]   ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors [J].
Lutterbach, B ;
Westendorf, JJ ;
Linggi, B ;
Patten, A ;
Moniwa, M ;
Davie, JR ;
Huynh, KD ;
Bardwell, VJ ;
Lavinsky, RM ;
Rosenfeld, MG ;
Glass, C ;
Seto, E ;
Hiebert, SW .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :7176-7184
[9]  
NEGRINI M, 1993, CANCER RES, V53, P4489
[10]   Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors [J].
Pedersen-Bjergaard, J ;
Andersen, MK ;
Johansson, B .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1897-1898